title: Are sTWEAK and IL-17A Levels in Inflammatory Bowel Disease Associated with Disease Activity and Etiopathogenesis?
abstract: BACKGROUND
  We aimed to identify the levels of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and interleukin 17A (IL-17A) in inflammatory bowel disease (IBD) and to examine their relationship with disease activity.
  
  
  METHODS
  A total of 92 patients with IBD, in which 54 patients were diagnosed with ulcerative colitis and 38 patients with Crohn's disease (CD), and 104 healthy controls were included in the study. The Rachmilewitz endoscopic activity index was calculated in ulcerative colitis, and the CD activity index was calculated in CD.
  
  
  RESULTS
  sTWEAK (P < 0.001) and IL-17A (P = 0.006) levels were higher in the IBD group than in the control group. Both in the IBD group and ulcerative colitis and CD subgroups, in active patients, sTWEAK and IL-17A levels were found to be higher than in inactive and control groups. In the IBD group, a positive correlation was determined between sTWEAK and IL-17A, and C-reactive protein, endoscopic activity index, and CD activity index. In multivariable regression analysis, C-reactive protein and sTWEAK levels were determined to be an independent risk factor for both endoscopic activity index and CD activity index. In receiver operating curve analysis, the sTWEAK level was determined to predict IBD with high sensitivity and specificity with a value of >588.34 pg/mL and activity with a value of >669.28 pg/mL.
  
  
  CONCLUSIONS
  Based on these results, we ascertain that sTWEAK has a role in etiopathogenesis of IBD. In addition, we believe that sTWEAK could be used as a marker for both disease activity criteria and treatment monitoring.
authors.affiliation: *Department of Gastroenterology, Turkey Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey; †Department of Internal Medicine, Ankara Numune Training and Research Hospital, Ankara, Turkey; ‡Department of Microbiology, Turkey Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey; and §Department of Immunology and Allergy, Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Ankara, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Kaplan
authors.forename: Mahmut
authors.initials: M
authors.lastname: Yuksel
authors.forename: Ihsan
authors.initials: I
authors.lastname: Ates
authors.forename: Zeki Mesut
authors.initials: ZM
authors.lastname: Yaln Kilic
authors.forename: Hasan
authors.initials: H
authors.lastname: Kilic
authors.forename: Hale
authors.initials: H
authors.lastname: Ates
authors.forename: Ertugrul
authors.initials: E
authors.lastname: Kayacetin
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000378:metabolism*; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D000074049:Cytokine TWEAK; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000209:etiology* / Q000378:metabolism / Q000473:pathology*; D020381:Interleukin-17 / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012372:ROC Curve; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D048069:Tumor Necrosis Factors / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D000074049:Cytokine TWEAK; C508717:IL17A protein, human; D020381:Interleukin-17; C109743:TNFSF12 protein, human; D014409:Tumor Necrosis Factor-alpha; D048069:Tumor Necrosis Factors; D002097:C-Reactive Protein